BPC-157: what the early research can tell us

Start with the experiment

BPC-157 often appears in discussions about tissue repair. To understand why, begin with an individual experiment rather than a list of claimed benefits. A 2011 study by Chang and colleagues examined cells derived from rat Achilles tendons and tendon tissue maintained outside the animal. The researchers reported greater cell movement and tissue outgrowth, alongside improved cell survival under an experimental stress condition. They also investigated signaling associated with those changes.

That is a useful biological observation. It gives researchers something specific to investigate and potentially reproduce. It does not establish that a person with a tendon injury will regain strength sooner, return to sport earlier, or experience fewer complications. None of those human outcomes was measured in that experiment.

There is human literature, with substantial limits

It would be inaccurate to say that BPC-157 has never been studied in people. One frequently cited 2021 report by Lee and Padgett reviewed a small group with knee pain. Sixteen people were reached for follow-up, and many described improvement. Some had received BPC-157 alone; others had received a combination that included thymosin beta-4.

The report was retrospective, without a randomized comparison group. It also lacked specific instruments for measuring function, stiffness, daily activity or quality of life. Those details matter: a report of less pain cannot, by itself, demonstrate repaired cartilage or a healed tendon. The design cannot reliably separate an intervention's effect from other explanations for improvement.

Safety remains an open research question

In its briefing prepared for the July 2026 Pharmacy Compounding Advisory Committee meeting, FDA identified five clinical studies involving BPC-157 but found insufficient information to characterize its clinical safety profile. The assessment also described uncertainty around product characterization and possible immune responses associated with some formulations and routes. The absence of a serious event in a small report cannot establish safety across a much larger population or over longer periods.

What would make the evidence more useful?

For recovery research, useful next steps would include clearly defined injuries, a suitable comparison group, consistent rehabilitation, prespecified functional outcomes and meaningful follow-up. Researchers would also need a well-characterized test material and systematic collection of adverse events. Those features would help turn an interesting signal into a result that can be interpreted with greater confidence.

Our reading is that BPC-157 remains a subject for further investigation. Early findings can justify a research question; they do not establish a human recovery benefit or demonstrate the performance of a commercially sold research product.

Sources & further reading

• Chang et al. (2011): tendon explants and fibroblast experiments
• Lee and Padgett (2021): retrospective knee-pain report
• FDA (2026): BPC-157 briefing for the Pharmacy Compounding Advisory Committee